<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37041269</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature reviews. Rheumatology</Title><ISOAbbreviation>Nat Rev Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Precision medicine in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>331</StartPage><EndPage>342</EndPage><MedlinePgn>331-342</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41584-023-00948-y</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is an autoimmune disease that has diverse clinical manifestations, ranging from restricted cutaneous involvement to life-threatening systemic organ involvement. The heterogeneity of pathomechanisms that lead to SLE contributes to between-patient variation in clinical phenotype and treatment response. Ongoing efforts to dissect cellular and molecular heterogeneity in SLE could facilitate the future development of stratified treatment recommendations and precision medicine, which is a considerable challenge for SLE. In particular, some genes involved in the clinical heterogeneity of SLE and some phenotype-related loci (STAT4, IRF5, PDGF genes, HAS2, ITGAM and SLC5A11) have an association with clinical features of the disease. An important part is also played by epigenetic varation (in DNA methylation, histone modifications and microRNAs) that influences gene expression and affects cell function without modifying the genome sequence. Immune profiling can help to identify an individual's specific response to a therapy and can potentially predict outcomes, using techniques such as flow cytometry, mass cytometry, transcriptomics, microarray analysis and single-cell RNA sequencing. Furthermore, the identification of novel serum and urinary biomarkers would enable the stratification of patients according to predictions of long-term outcomes and assessments of potential response to therapy.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fasano</LastName><ForeName>Serena</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4718-4551</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Precision Medicine, Universit&#xe0; Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy. serena.fasano@unicampania.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milone</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Precision Medicine, Universit&#xe0; Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicoletti</LastName><ForeName>Giovanni Francesco</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Multidisciplinary Department of Medical-Surgical and Dental Specialties, Universit&#xe0; Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isenberg</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-9514-2455</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Division of Medicine, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccia</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Precision Medicine, Universit&#xe0; Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy. Francesco.ciccia@unicampania.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Rev Rheumatol</MedlineTA><NlmUniqueID>101500080</NlmUniqueID><ISSNLinking>1759-4790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C457199">SLC5A11 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051247">Sodium-Glucose Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051247" MajorTopicYN="N">Sodium-Glucose Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37041269</ArticleId><ArticleId IdType="doi">10.1038/s41584-023-00948-y</ArticleId><ArticleId IdType="pii">10.1038/s41584-023-00948-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lisnevskaia, L., Murphy, G. &amp; Isenberg, D. A. Systemic lupus erythematosus. Lancet 384, 1878&#x2013;1888 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24881804</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(14)60128-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211&#x2013;221 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens, C. et al. AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). Ann. Rheum. Dis. 79, 172&#x2013;173 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-eular.5010</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736&#x2013;745 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30926722</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vollenhoven, R. F. et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci. Med. 8, e000538 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34819388</ArticleId><ArticleId IdType="pmc">8614136</ArticleId><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Vizcaya, A. &amp; Isenberg, D. A. Clinical trials in systemic lupus erythematosus &#x2013; the dilemma. Why have phase III trials failed to confirm the promising results of phase II trials. Ann. Rheum. Dis. 82, 169&#x2013;174 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36202589</ArticleId><ArticleId IdType="doi">10.1136/ard-2022-222839</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitzalis, C., Choy, E. H. S. &amp; Buch, M. H. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat. Rev. Rheumatol. 16, 590&#x2013;599 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32887976</ArticleId><ArticleId IdType="doi">10.1038/s41584-020-0491-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, 11 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal, M. et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr. Opin. Immunol. 67, 87&#x2013;94 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33246136</ArticleId><ArticleId IdType="pmc">8054829</ArticleId><ArticleId IdType="doi">10.1016/j.coi.2020.10.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckerle, C. E. et al. Network analysis of associations between serum interferon-&#x3b1; activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 63, 1044&#x2013;1053 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21162028</ArticleId><ArticleId IdType="pmc">3068224</ArticleId><ArticleId IdType="doi">10.1002/art.30187</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610&#x2013;2615 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12604793</ArticleId><ArticleId IdType="pmc">151388</ArticleId><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow, M. K., Kirou, K. A. &amp; Wohlgemuth, J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36, 481&#x2013;490 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14984025</ArticleId><ArticleId IdType="doi">10.1080/08916930310001625952</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg, D. et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74, 2006&#x2013;2015 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">24951103</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2013-205067</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 70, 266&#x2013;276 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29073347</ArticleId><ArticleId IdType="pmc">6099253</ArticleId><ArticleId IdType="doi">10.1002/art.40360</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, C. et al. Post hoc analysis of the phase II/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol. 69, 122&#x2013;130 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27390168</ArticleId><ArticleId IdType="doi">10.1002/art.39809</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand, E. F. et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology 59, 2930&#x2013;2938 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32107560</ArticleId><ArticleId IdType="pmc">7516108</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaa029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace, D. J. et al. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology 60, 5379&#x2013;5389 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33547784</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keab115</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, R. A. et al. Cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100&#x2013;107 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34615636</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum. 64, 1215&#x2013;1226 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22231479</ArticleId><ArticleId IdType="doi">10.1002/art.34359</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy, V. et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology 56, 1227&#x2013;1237 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28407142</ArticleId><ArticleId IdType="pmc">5808665</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kex067</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas-Larrauri, F. &amp; Yamazaki-Nakashimada, M. A. Systemic lupus erythematosus: is it one disease? Reumatol. Clin. 12, 274&#x2013;281 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26922326</ArticleId><ArticleId IdType="doi">10.1016/j.reuma.2016.01.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Vega, A. et al. Recent findings on genetics of systemic autoimmune diseases. Curr. Opin. Immunol. 22, 698&#x2013;705 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2010.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon-Segovia, D. et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 52, 1138&#x2013;1147 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15818688</ArticleId><ArticleId IdType="doi">10.1002/art.20999</ArticleId></ArticleIdList></Reference><Reference><Citation>International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40, 204&#x2013;210 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.81</ArticleId></ArticleIdList></Reference><Reference><Citation>Hom, G. et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 358, 900&#x2013;909 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18204098</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0707865</ArticleId></ArticleIdList></Reference><Reference><Citation>Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005&#x2013;D1012 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30445434</ArticleId><ArticleId IdType="doi">10.1093/nar/gky1120</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, Y. &amp; Tsao, B. P. Advances in lupus genetics and epigenetics. Curr. Opin. Rheumatol. 26, 482&#x2013;492 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25010439</ArticleId><ArticleId IdType="pmc">4222581</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamitaki, N. et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature 582, 577&#x2013;581 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32499649</ArticleId><ArticleId IdType="pmc">7319891</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2277-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolio, T. A. Bringing genome-wide association findings into clinical use. Nat. Rev. Genet. 14, 549&#x2013;558 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23835440</ArticleId><ArticleId IdType="doi">10.1038/nrg3523</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, G. J. et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 605, 349&#x2013;356 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35477763</ArticleId><ArticleId IdType="pmc">9095492</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04642-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Brierley, M. M. &amp; Fish, E. N. IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. J. Interferon Cytokine Res. 22, 835&#x2013;845 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/107999002760274845</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, K. E. et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 4, e1000084 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18516230</ArticleId><ArticleId IdType="pmc">2377340</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1000084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson, S. et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum. Mol. Genet. 17, 2868&#x2013;2876 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18579578</ArticleId><ArticleId IdType="pmc">2525501</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddn184</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenungsson, E. et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann. Rheum. Dis. 69, 834&#x2013;840 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19762360</ArticleId><ArticleId IdType="doi">10.1136/ard.2009.115535</ArticleId></ArticleIdList></Reference><Reference><Citation>Restivo, V. et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun. Rev. 21, 102925 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34454117</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2021.102925</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes, B., Lubyova, B. &amp; Pitha, P. M. On the role of IRF in host defense. J. Interferon Cytokine Res. 22, 59&#x2013;71 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/107999002753452665</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, D. et al. Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching. Eur. J. Immunol. 42, 1477&#x2013;1487 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22678902</ArticleId><ArticleId IdType="pmc">3684952</ArticleId><ArticleId IdType="doi">10.1002/eji.201141642</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, S. et al. Inhibition of IRF5 hyperactivation protects from lupus onset and severity. J. Clin. Invest. 130, 6700&#x2013;6717 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32897883</ArticleId><ArticleId IdType="pmc">7685739</ArticleId><ArticleId IdType="doi">10.1172/JCI120288</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins, A. A. et al. IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. J. Immunol. 194, 1467&#x2013;1479 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25595782</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1402807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf, T., Eitner, F. &amp; Floege, J. The PDGF family in renal fibrosis. Pediatr. Nephrol. 27, 1041&#x2013;1050 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21597969</ArticleId><ArticleId IdType="doi">10.1007/s00467-011-1892-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, S. A. et al. International Consortium for Systemic Lupus Erythematosus Genetics. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J. Am. Soc. Nephrol. 25, 2859&#x2013;2870 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24925725</ArticleId><ArticleId IdType="pmc">4243339</ArticleId><ArticleId IdType="doi">10.1681/ASN.2013050446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurogi, Y. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med. Res. Rev. 23, 15&#x2013;31 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12424751</ArticleId><ArticleId IdType="doi">10.1002/med.10028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoja, C. et al. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 70, 97&#x2013;103 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16688113</ArticleId><ArticleId IdType="doi">10.1038/sj.ki.5001528</ArticleId></ArticleIdList></Reference><Reference><Citation>Feusi, E. et al. Enhanced hyaluronan synthesis in the MRL-Fas(lpr) kidney: role of cytokines. Nephron 83, 66&#x2013;73 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10461038</ArticleId><ArticleId IdType="doi">10.1159/000045475</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerholm, S. C. et al. The CD11b-integrin (ITGAM) and systemic lupus erythematosus. Lupus 22, 657&#x2013;663 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23753600</ArticleId><ArticleId IdType="doi">10.1177/0961203313491851</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;rvinen, T. M. et al. Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS ONE 5, e14212 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21151989</ArticleId><ArticleId IdType="pmc">2996302</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0014212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim-Howard, X. et al. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann. Rheum. Dis. 69, 1329&#x2013;1332 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19939855</ArticleId><ArticleId IdType="doi">10.1136/ard.2009.120543</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, K. E. et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 7, e1001311 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21379322</ArticleId><ArticleId IdType="pmc">3040652</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1001311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, S. A. et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet. 7, e1001323 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21408207</ArticleId><ArticleId IdType="pmc">3048371</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1001323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, R. C. et al. Genetic variants that are associated with neuropsychiatric systemic lupus erythematosus. J. Rheumatol. 43, 541&#x2013;551 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26773105</ArticleId><ArticleId IdType="doi">10.3899/jrheum.150884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai, L. J. et al. The sodium-dependent glucose cotransporter SLC5A11 as an autoimmune modifier gene in SLE. Tissue Antigens 71, 14&#x2013;26 (2008).</Citation></Reference><Reference><Citation>Zan, H. Epigenetics in lupus. Autoimmunity 47, 213&#x2013;214 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24826881</ArticleId><ArticleId IdType="doi">10.3109/08916934.2014.915393</ArticleId></ArticleIdList></Reference><Reference><Citation>De Oliveira, N. F. P., de Souza, B. F. &amp; de Castro Co&#xea;lho, M. UV radiation and its relation to DNA methylation in epidermal cells: a review. Epigenomes 4, 23 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">34968303</ArticleId><ArticleId IdType="pmc">8594722</ArticleId><ArticleId IdType="doi">10.3390/epigenomes4040023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawalha, A. H. et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun. 9, 368&#x2013;378 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18523434</ArticleId><ArticleId IdType="pmc">2825163</ArticleId><ArticleId IdType="doi">10.1038/gene.2008.29</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams, D. E. &amp; Shao, W. H. Epigenetic alterations in immune cells of systemic lupus erythematosus and therapeutic implications. Cells 11, 506 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35159315</ArticleId><ArticleId IdType="pmc">8834103</ArticleId><ArticleId IdType="doi">10.3390/cells11030506</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861&#x2013;874 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22094949</ArticleId><ArticleId IdType="doi">10.1038/nrg3074</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Hernandez, J. et al. Increased urinary exosomal microRNAs in patients with systemic lupus erythematosus. PLoS ONE 10, e0138618 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26390437</ArticleId><ArticleId IdType="pmc">4577109</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0138618</ArticleId></ArticleIdList></Reference><Reference><Citation>So, B. Y. F., Yap, D. Y. H. &amp; Chan, T. M. MicroRNAs in lupus nephritis&#x2014;role in disease pathogenesis and clinical applications. Int. J. Mol. Sci. 22, 10737 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34639078</ArticleId><ArticleId IdType="pmc">8509214</ArticleId><ArticleId IdType="doi">10.3390/ijms221910737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi, M. et al. Immunological involvement of microRNAs in the key events of systemic lupus erythematosus. Front. Immunol. 12, 699684 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34408748</ArticleId><ArticleId IdType="pmc">8365877</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.699684</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, R., Hu, Y. &amp; Bo, L. Genome variation and precision medicine in systemic lupus erythematosus. Methods Mol. Biol. 2204, 193&#x2013;203 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32710326</ArticleId><ArticleId IdType="doi">10.1007/978-1-0716-0904-0_17</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856&#x2013;860 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26121088</ArticleId><ArticleId IdType="doi">10.1038/ng.3314</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711&#x2013;723 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12642603</ArticleId><ArticleId IdType="pmc">2193846</ArticleId><ArticleId IdType="doi">10.1084/jem.20021553</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551&#x2013;565 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27040498</ArticleId><ArticleId IdType="pmc">5426482</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.03.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Shobha, V. et al. Identification and stratification of systemic lupus erythematosus patients into two transcriptionally distinct clusters based on IFN-I signature. Lupus 30, 762&#x2013;774 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33497307</ArticleId><ArticleId IdType="doi">10.1177/0961203321990107</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes, W. A. et al. Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus. JCI Insight 5, e122312 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31971918</ArticleId><ArticleId IdType="pmc">7101149</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.122312</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga, M. et al. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology 59, 2272&#x2013;2281 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31840179</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kez584</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan, C. et al. Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus 27, 681&#x2013;687 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29310537</ArticleId><ArticleId IdType="pmc">5888773</ArticleId><ArticleId IdType="doi">10.1177/0961203317749746</ArticleId></ArticleIdList></Reference><Reference><Citation>Billi, A. C. et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci. Transl Med. 14, eabn2263 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35476593</ArticleId><ArticleId IdType="pmc">9169615</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abn2263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava, A. et al. Integrated urine proteomics and renal single-cell genomics identify an IFN-&#x3b3; response gradient in lupus nephritis. JCI Insight 5, e138345 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32396533</ArticleId><ArticleId IdType="pmc">7406291</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.138345</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, M. et al. Diverse roles of NETosis in the pathogenesis of lupus. Front. Immunol. 13, 895216 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35686129</ArticleId><ArticleId IdType="pmc">9170953</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.895216</ArticleId></ArticleIdList></Reference><Reference><Citation>Decout, A. et al. The cGAS&#x2013;STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548&#x2013;569 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33833439</ArticleId><ArticleId IdType="pmc">8029610</ArticleId><ArticleId IdType="doi">10.1038/s41577-021-00524-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222&#x2013;233 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20039413</ArticleId><ArticleId IdType="pmc">4548300</ArticleId><ArticleId IdType="doi">10.1002/art.27233</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri, M. et al. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med. Genomics 12, 4 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30626389</ArticleId><ArticleId IdType="pmc">6327466</ArticleId><ArticleId IdType="doi">10.1186/s12920-018-0468-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Northcott, M. et al. Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study. Lancet Rheumatol. 3, e357&#x2013;e370 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00006-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Northcott, M. et al. Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Sci. Med. 9, e000625 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35197305</ArticleId><ArticleId IdType="pmc">8867321</ArticleId><ArticleId IdType="doi">10.1136/lupus-2021-000625</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner, T. et al. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J. Immunol. Methods 363, 187&#x2013;197 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20598709</ArticleId><ArticleId IdType="doi">10.1016/j.jim.2010.06.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Md Yusof, M. Y. et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann. Rheum. Dis. 76, 1829&#x2013;1836 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28684557</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-211191</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 75, 1407&#x2013;1415 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207776</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalapino, K. J. et al. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol. 177, 1451&#x2013;1459 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16849451</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.177.3.1451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo, S. et al. Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients. Arthritis Rheumatol. 69, 2029&#x2013;2037 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28605137</ArticleId><ArticleId IdType="doi">10.1002/art.40180</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki, T. et al. Longitudinal immune cell profiling in early systemic lupus erythematosus. Arthritis Rheumatol. 74, 1808&#x2013;1821 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35644031</ArticleId><ArticleId IdType="doi">10.1002/art.42248</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Gorman, W. E. et al. Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients. J. Autoimmun. 81, 74&#x2013;89 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2017.03.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Panousis, N. I. et al. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann. Rheum. Dis. 78, 1079&#x2013;1089 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31167757</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-214379</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehar-Belaid, D. et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat. Immunol. 21, 1094&#x2013;1106 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32747814</ArticleId><ArticleId IdType="pmc">7442743</ArticleId><ArticleId IdType="doi">10.1038/s41590-020-0743-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez, R. K. et al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science 376, eabf1970 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35389781</ArticleId><ArticleId IdType="pmc">9297655</ArticleId><ArticleId IdType="doi">10.1126/science.abf1970</ArticleId></ArticleIdList></Reference><Reference><Citation>Der, E. et al. Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight 2, e93009 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28469080</ArticleId><ArticleId IdType="pmc">5414553</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.93009</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlap, G. S. et al. Single-cell transcriptomics reveals distinct effector profiles of infiltrating T cells in lupus skin and kidney. JCI Insight 7, e156341 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35290245</ArticleId><ArticleId IdType="pmc">9089784</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.156341</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, G. A. et al. Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatol. 2, e485&#x2013;e496 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32818204</ArticleId><ArticleId IdType="pmc">7425802</ArticleId><ArticleId IdType="doi">10.1016/S2665-9913(20)30168-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano, M. et al. Distinct transcriptome architectures underlying lupus establishment and exacerbation. Cell 185, 3375&#x2013;3389 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35998627</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.07.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, H., Nagafuchi, Y. &amp; Fujio, K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules 11, 928 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34206696</ArticleId><ArticleId IdType="pmc">8301935</ArticleId><ArticleId IdType="doi">10.3390/biom11070928</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer, M. et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78, 1151&#x2013;1159 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31383717</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, R. et al. Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Exp. Ther. Med. 18, 4067&#x2013;4075 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31616519</ArticleId><ArticleId IdType="pmc">6781829</ArticleId></ArticleIdList></Reference><Reference><Citation>Narumi, S. et al. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine 12, 1561&#x2013;1565 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11023674</ArticleId><ArticleId IdType="doi">10.1006/cyto.2000.0757</ArticleId></ArticleIdList></Reference><Reference><Citation>Capecchi, R. et al. New biomarkers in SLE: from bench to bedside. Rheumatology 59, v12&#x2013;v18 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32911542</ArticleId><ArticleId IdType="pmc">7719038</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaa484</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoso-Loyo, H. et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 56, 1242&#x2013;1250 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17393453</ArticleId><ArticleId IdType="doi">10.1002/art.22451</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka, N. et al. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus. PLoS ONE 15, e0227069 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31986153</ArticleId><ArticleId IdType="pmc">6984724</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0227069</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Hoogen, L. L. et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann. Rheum. Dis. 77, 1810&#x2013;1814 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30185417</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-213497</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira, J. J. et al. The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Res. Ther. 20, 152 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30053827</ArticleId><ArticleId IdType="pmc">6062988</ArticleId><ArticleId IdType="doi">10.1186/s13075-018-1649-1</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sherbiny, Y. M. et al. B cell tetherin: a flow cytometric cell-specific assay for response to type I interferon predicts clinical features and flares in systemic lupus erythematosus. Arthritis Rheumatol. 72, 769&#x2013;779 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31804007</ArticleId><ArticleId IdType="pmc">8653884</ArticleId><ArticleId IdType="doi">10.1002/art.41187</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollars, E. et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Sci. Med. 2, e000063 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26113988</ArticleId><ArticleId IdType="pmc">4477150</ArticleId><ArticleId IdType="doi">10.1136/lupus-2014-000063</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodorou, E. et al. B-cell activating factor and related genetic variants in lupus related atherosclerosis. J. Autoimmun. 92, 87&#x2013;92 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29859654</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2018.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun, H. Y. et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27, 461&#x2013;466 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17587156</ArticleId><ArticleId IdType="doi">10.1007/s10875-007-9104-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q., Sun, L. &amp; Jin, L. Spot urine protein/creatinine ratio is unreliable estimate of 24 h proteinuria in lupus nephritis when the histological scores of activity index are higher. Lupus 24, 943&#x2013;947 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25670710</ArticleId><ArticleId IdType="doi">10.1177/0961203315570688</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes Marques, M. et al. Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? Clin. Kidney J. 6, 590&#x2013;594 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">26069827</ArticleId><ArticleId IdType="pmc">4438366</ArticleId><ArticleId IdType="doi">10.1093/ckj/sft118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y. H. &amp; Song, G. G. Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis. Z. Rheumatol. 76, 357&#x2013;363 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27278779</ArticleId><ArticleId IdType="doi">10.1007/s00393-016-0109-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell, S. et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J. Immunol. 176, 1889&#x2013;1898 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16424220</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.176.3.1889</ArticleId></ArticleIdList></Reference><Reference><Citation>Xuejing, Z. et al. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J. Biomed. Biotechnol. 2012, 359647 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22719208</ArticleId><ArticleId IdType="pmc">3375113</ArticleId><ArticleId IdType="doi">10.1155/2012/359647</ArticleId></ArticleIdList></Reference><Reference><Citation>Suttichet, T. B. et al. Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study. Lupus Sci. Med. 6, e000298 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31168397</ArticleId><ArticleId IdType="pmc">6519400</ArticleId><ArticleId IdType="doi">10.1136/lupus-2018-000298</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, Z. et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J. Immunol. 179, 7949&#x2013;7958 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18025243</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.179.11.7949</ArticleId></ArticleIdList></Reference><Reference><Citation>Supavekin, S. et al. Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 63, 1714&#x2013;1724 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12675847</ArticleId><ArticleId IdType="doi">10.1046/j.1523-1755.2003.00928.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein, T. et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology 49, 960&#x2013;971 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20144927</ArticleId><ArticleId IdType="pmc">2853702</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kep468</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C. C. et al. Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis. Arthritis Res. Ther. 20, 6 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29325582</ArticleId><ArticleId IdType="pmc">5765646</ArticleId><ArticleId IdType="doi">10.1186/s13075-017-1498-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano, S. et al. Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus: an exploratory study. Rheumatology 59, 3193&#x2013;3200 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32211780</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaa074</ArticleId></ArticleIdList></Reference><Reference><Citation>Garantziotis, P. et al. Molecular taxonomy of systemic lupus erythematosus through data-driven patient stratification: molecular endotypes and cluster-tailored drugs. Front. Immunol. 13, 860726 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35615355</ArticleId><ArticleId IdType="pmc">9125979</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.860726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. F. et al. Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus erythematosus (SLE) and evaluation of SLE genetics in drug repositioning. Ann. Rheum. Dis. 77, 1078&#x2013;1084 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29625966</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-213093</ArticleId></ArticleIdList></Reference><Reference><Citation>Toro-Dom&#xed;nguez, D., Carmona-S&#xe1;ez, P. &amp; Alarc&#xf3;n-Riquelme, M. E. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis. Arthritis Res. Ther. 19, 54 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28284231</ArticleId><ArticleId IdType="pmc">5346251</ArticleId><ArticleId IdType="doi">10.1186/s13075-017-1263-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai, Z. W. et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet 391, 1186&#x2013;1196 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29551338</ArticleId><ArticleId IdType="pmc">5891154</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(18)30485-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Toro-Dom&#xed;nguez, D. et al. Differential treatments based on drug-induced gene expression signatures and longitudinal systemic lupus erythematosus stratification. Sci. Rep. 9, 15502 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31664045</ArticleId><ArticleId IdType="pmc">6820741</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-51616-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard, E. L. et al. Analysis of gene expression from systemic lupus erythematosus synovium reveals myeloid cell-driven pathogenesis of lupus arthritis. Sci. Rep. 10, 17361 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33060686</ArticleId><ArticleId IdType="pmc">7562741</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-74391-4</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>